Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, demonstrating strong growth across its key markets and therapeutic segments.

Financial Highlights

• Revenue from operations increased by 11% year-over-year to Rs. 3,178.00 crores
• Operating EBITDA grew by 14% to Rs. 1,032.00 crores, with a margin of 32.5%
• Net profit after tax surged by 20% to Rs. 548.00 crores
• R&D expenditure stood at Rs. 157.00 crores, representing 5% of revenue

Market Performance

India

The company's performance in its home market remained strong:

• India revenues rose by 11% to Rs. 1,811.00 crores
• Chronic business grew by 13%, outpacing the Indian Pharmaceutical Market (IPM) growth of 9%
• Torrent now has 21 brands in the Top 500 brands in IPM, with 14 brands generating over Rs. 100.00 crores in sales

International Markets

Torrent Pharma also reported solid growth in its key international markets:

Operational Performance

The company's gross margin remained stable at 76%, while the operating EBITDA margin improved slightly to 32.5%. Notably, the reported operating EBITDA includes acquisition-related one-off expenses of Rs. 15.00 crores. Adjusting for these one-time costs, the operating EBITDA stands at Rs. 1,047.00 crores with a margin of 32.9%.

R&D and Product Pipeline

Torrent Pharmaceuticals continues to invest significantly in research and development:

• R&D spending increased by 16% year-over-year to Rs. 157.00 crores
• The company has 62 products under review by ANVISA (Brazilian Health Regulatory Agency)

Market Position

Torrent Pharma has strengthened its position in key therapeutic segments:

• Ranked 7th in the Indian Pharmaceuticals Market
• Among the Top 5 in Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology segments
• Approximately 76% of its India revenues come from chronic and sub-chronic therapies

Global Presence

The company has expanded its global footprint:

• Present in over 50 countries
• Ranked No. 1 amongst Indian pharma companies in Brazil and Germany
• Operates 8 manufacturing facilities, including 5 USFDA-approved sites

Torrent Pharmaceuticals' strong performance reflects its robust product portfolio, strategic market presence, and continued focus on research and development. The company's ability to outperform market growth in key segments and geographies positions it well for sustained growth in the coming quarters.

Torrent Pharmaceuticals , a prominent player in the Indian pharmaceutical sector, recently witnessed significant market activity and has scheduled important corporate events. Here's a breakdown of the latest developments:

Major Block Trade on NSE

Torrent Pharmaceuticals executed a substantial block trade on the National Stock Exchange (NSE), showcasing strong institutional interest in the company's stock. The transaction details are as follows:

This block trade represents a notable institutional movement in Torrent Pharmaceuticals' shares, potentially indicating investor confidence in the company's prospects.

Upcoming Financial Results and Investor Conference Call

In a recent corporate announcement, Torrent Pharmaceuticals has informed stakeholders about two significant upcoming events:

1. Board Meeting for Financial Results: The company's Board of Directors is scheduled to meet on Monday, July 28, to consider and approve the financial results for the quarter ended June 30. The board will review:

   • Audited Financial Results on a Standalone basis
   • Unaudited Financial Results (with limited review) on a Consolidated basis

2. Investor/Analyst Conference Call: Following the board meeting, Torrent Pharmaceuticals will host a teleconference with investors and analysts on July 28, at 6:30 PM. This call will discuss the company's financial performance for the quarter ended June 30.

Additional Corporate Actions

During the upcoming board meeting, the directors will also consider the issuance of Unsecured/Secured Redeemable Non-Convertible Debentures/Bonds through private placement. This consideration suggests that Torrent Pharmaceuticals might be exploring debt financing options, potentially for capital expenditure, refinancing existing debt, or other corporate purposes.

Investors and market participants will be keenly watching these developments, as they could provide insights into Torrent Pharmaceuticals' financial health, future strategies, and market position in the competitive pharmaceutical industry.